Raloxifene is a synthetic selective estrogen receptor modulator used in the treatment of osteoporosis in postmenopausal women. It functions by mimicking estrogen activity in bone tissue to reduce bone resorption while blocking estrogen effects in the breast and uterus. The drug binds to estrogen receptors and recruits co-activators or co-repressors depending on the tissue thereby altering the transcription of genes involved in bone metabolism. By decreasing the rate of bone breakdown Raloxifene helps maintain bone mineral density and lowers the risk of vertebral fractures. The active metabolite influences calcium homeostasis and promotes osteoblast-mediated bone formation thereby contributing to overall skeletal strength. Through these actions Raloxifene provides a non-estrogenic therapy that targets estrogen-responsive pathways to protect bone without stimulating breast or uterine tissue.

Raloxifene is a selective estrogen receptor modulator used primarily for the prevention and treatment of osteoporosis in postmenopausal women. Its therapeutic role involves reducing bone resorption and maintaining bone mineral density thereby lowering fracture risk. The drug exerts its pharmacological activity by binding to estrogen receptors in bone tissue and modulating their signaling in a tissue specific manner. By acting as an antagonist in postmenopausal bone Raloxifene blocks estrogen stimulated osteoclast formation while sparing the lipid lowering effects of estrogen in other tissues. This selective antagonism leads to decreased bone turnover and net bone preservation which underlies its clinical benefit. Overall Raloxifene functions as a synthetic compound that mimics estrogen in some tissues while antagonizing it in others achieving a balanced modulation of bone remodeling pathways.

Raloxifene may cause hot flashes in some individuals. It can lead to nausea or mild stomach discomfort. Swelling of the feet or ankles is a reported side effect. Some users experience muscle cramps in the legs. Blood clot risk may increase with prolonged immobility. Vision changes such as blurred sight have been observed. Weight gain or loss can occur without a clear pattern.

Raloxifene may cause hot flashes that are similar to menopausal symptoms. It is associated with an elevated risk of deep vein thrombosis and pulmonary embolism. Some users experience joint pain or stiffness that can affect mobility. The medication can lead to mild nausea or gastrointestinal discomfort. It has been linked to rare cases of cataract formation that may affect vision. Long-term use may also influence bone density in a way that requires monitoring.